ストックスクリーナーアプリを入手
39.52
1.14%
-0.1819
前日終値:
$39.34
開ける：
$39.39
24時間の取引高:
6,044
Relative Volume:
0.02
時価総額：
$3.00B
収益：
$13.17M
当期純損益:
$-199.06M
株価収益率:
-15.87
EPS:
-2.49
ネットキャッシュフロー:
$-156.53M
1週間 パフォーマンス:
-6.85%
1か月 パフォーマンス:
-12.03%
6か月 パフォーマンス:
-0.23%
1年 パフォーマンス:
+29.50%
1日の値動き範囲:
$38.71
$39.87
1週間の範囲:
$37.34
$41.42
52週間の値動き範囲:
$28.20
$50.99
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
名前
Xenon Pharmaceuticals Inc
セクター
電話
(604) 484-3300
住所
200 - 3650 GILMORE WAY, BURNABY
XENE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| XENE | 39.55 | 3.00B | 13.17M | -199.06M | -156.53M | -2.49 |
| VRTX | 446.63 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.99 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.16 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.33 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-10-01 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-04 | 開始されました | Citigroup | Buy |
| 2023-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 開始されました | Goldman | Buy |
| 2022-12-12 | 開始されました | Cowen | Outperform |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-10-19 | 開始されました | Raymond James | Outperform |
| 2022-08-29 | 開始されました | BofA Securities | Buy |
| 2022-07-21 | 開始されました | JP Morgan | Overweight |
| 2021-10-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-10-02 | 開始されました | SVB Leerink | Outperform |
| 2020-07-21 | 開始されました | Needham | Buy |
| 2020-06-01 | 再開されました | Jefferies | Buy |
| 2020-03-25 | 開始されました | Wedbush | Outperform |
| 2020-01-08 | 開始されました | William Blair | Outperform |
| 2019-09-20 | 開始されました | Guggenheim | Buy |
| 2018-08-08 | 繰り返されました | Stifel | Buy |
| 2017-03-13 | 開始されました | Jefferies | Buy |
| 2016-10-21 | 開始されました | Stifel | Buy |
| 2016-09-26 | 開始されました | Guggenheim | Buy |
| 2016-04-14 | 繰り返されました | Jefferies | Buy |
| 2015-10-30 | 再開されました | Jefferies | Buy |
| 2014-12-02 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Xenon Pharmaceuticals Inc (XENE) 最新ニュース
First Turn Management LLC Sells 14,658 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Investors Eye Opportunities With Xenon Pharmaceuticals - Evrim Ağacı
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap DownHere's What Happened - MarketBeat
Equities Analysts Issue Forecasts for XENE FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for XENE Reduced by Cantor Fitzgerald - MarketBeat
How to Take Advantage of moves in (XENE) - Stock Traders Daily
Q1 Earnings Forecast for XENE Issued By HC Wainwright - MarketBeat
What is Wedbush's Estimate for XENE FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Pessimistic View of XENE FY2024 Earnings - MarketBeat
Needham & Company LLC Reaffirms Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Stock Traders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
GSA Capital Partners LLP Purchases 30,830 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon to Present at Upcoming Investor Conferences - The Manila Times
Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2024 Earnings Call Transcript - Insider Monkey
Xenon Pharmaceuticals: Q3 Earnings Snapshot - mySA
Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlight - GuruFocus.com
Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Xenon Pharmaceuticals Reports Q3 2024 Progress and Outlook - TipRanks
Xenon Reports Q3 2024 Financial Results and Business Update - The Manila Times
Xenon Pharmaceuticals Reports $803M Cash Position, Advances Epilepsy Drug Pipeline | XENE Stock News - StockTitan
Earnings To Watch: Xenon Pharmaceuticals Inc (XENE) Reports Q3 2 - GuruFocus.com
TimesSquare Capital Management LLC Purchases 23,800 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Fiera Capital Corp Sells 28,679 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals (XENE) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Xenon to Report Q3 2024 Financial Results on November 12, 2024 - StockTitan
Harbor Capital Advisors Inc. Buys 23,947 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Allspring Global Investments Holdings LLC Sells 21,269 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
New Horizons in Tonic-clonic Seizure Market Exploring Future - openPR
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by abrdn plc - MarketBeat
Repligen Co. (NASDAQ:RGEN) Position Boosted by Blue Trust Inc. - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Brokerages - Defense World
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Creative Planning - Defense World
Creative Planning Buys 2,475 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Blue Trust Inc. Has $39,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Epilepsy Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat
Assenagon Asset Management S.A. Acquires 138,685 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
When (XENE) Moves Investors should Listen - Stock Traders Daily
SG Americas Securities LLC Sells 18,463 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Leerink Partnrs Has Negative Outlook of XENE FY2026 Earnings - MarketBeat
Stock Traders Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
How To Trade (XENE) - Stock Traders Daily
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe - Zacks Investment Research
Millennium Management LLC Increases Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc (XENE)’s Day in Review: Closing at 39.42, Down by -3.90 - The Dwinnex
Raymond James sets steady target on Xenon Pharmaceuticals By Investing.com - Investing.com UK
Xenon Pharmaceuticals Inc (XENE) 財務データ
収益
当期純利益
現金流量
EPS
Xenon Pharmaceuticals Inc (XENE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| GAROFALO ELIZABETH A. | Director |
Mar 08 '24 |
Sale |
45.69 |
2,092 |
95,583 |
0 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation |
Mar 07 '24 |
Option Exercise |
9.85 |
8,641 |
85,114 |
16,824 |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation |
Mar 07 '24 |
Sale |
46.28 |
7,137 |
330,290 |
8,398 |
| GANNON STEVEN | Director |
Mar 07 '24 |
Sale |
46.28 |
13,000 |
601,615 |
2,000 |
| AZAB MOHAMMAD | Director |
Dec 19 '23 |
Option Exercise |
9.85 |
4,320 |
42,552 |
74,225 |
| PATOU GARY | Director |
Dec 13 '23 |
Option Exercise |
9.55 |
14,402 |
137,487 |
29,951 |
| PATOU GARY | Director |
Dec 13 '23 |
Sale |
39.29 |
11,380 |
447,085 |
23,573 |
| PATOU GARY | Director |
Dec 13 '23 |
Sale |
41.05 |
7,598 |
311,898 |
4,902 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):